PerpEquities

Top analysts on stock perps · Analyst

Adam Ron (Bank of America Securities): analyst track record on stock perps

Adam Ron of Bank of America Securities on companies with stock perpetual futures: star rating, success rate, price-target accuracy, current calls and the measured perp reaction after each rating.

Stars4.1★
Success49%
Excess return+20.5%
rank#2,295
Ratings39
ratings on stock perps15

Track record

TipRanks data via FMP
12 months3 years
Ratings145
Stock18
Buy / hold / sell0 / 0 / 123 / 14 / 8
Upgrades / downgrades / initiations0 / 0 / 03 / 5 / 0
Price targets hit / missed1 / 0 (100%)21 / 16 (57%)
Avg. return after a rating (TipRanks)+30.3%+244.1%
Best / worst call+30.3% / +30.3%+3,758.3% / -35.2%

After buy calls: median 21-day move +1.7% · vs S&P 500 +0.6% · targets hit within a year 64% (n = 15)

Current calls on stock perps

StockCallTargetvs last closeDate
$OSCR Oscar Health, Inc.Sell · Maintained$25.00-23.3%Aug 6, 2026

Recent ratings

  • Aug 6, 2026 $OSCR: Maintained · Sell · $25.00 · article
  • Feb 5, 2025 $OSCR: Reiterated · Sell · $13.50 · article
  • Jan 30, 2025 $CI: Reiterated · Buy · $420 · article
  • Nov 6, 2024 $OSCR: Downgraded · Sell · $13.50 · article
  • Oct 31, 2024 $CI: Maintained · Buy · $420 · article
  • Oct 22, 2024 $CI: Reiterated · Buy · $420 · article
  • Aug 7, 2024 $OSCR: Reiterated · Hold · $21.00 · article
  • Jun 10, 2024 $OSCR: Reiterated · Hold · $21.00 · article
  • May 30, 2024 $OSCR: Downgraded · Hold · $21.00 · article
  • May 17, 2024 $OSCR: Reiterated · Buy · $25.00 · article
  • May 7, 2024 $OSCR: Reiterated · Buy · $22.00 · article
  • Feb 8, 2024 $OSCR: Reiterated · Buy · $20.00 · article
  • Dec 20, 2023 $OSCR: Reiterated · Buy · $10.00 · article
  • Dec 13, 2023 $OSCR: Maintained · Buy · $10.00 · article
  • Nov 2, 2023 $OSCR: Upgraded · Buy · $9.00 · article

Adam Ron4.1★ · 49% success · +20.5% excess return · TipRanks data via FMP · Source headlines via TheFly/StreetInsider (FMP). Reaction = venue-median perp move after our detection — an observation, not investment advice.